FEBRUARY 03, 2012

Browse Categories

Notice
  • Sorry! That page cannot be found.
Contribute to UroToday

Contribute to UroToday

Be a part of the published community of UroToday and promote awareness among your colleagues.

If you are interested in writing for UroToday Contact Us

editors@urotoday.com

Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
Urotoday Exclusives

BERKELEY, CA (UroToday.com) - An Optimistic Take on Recent Onset BPS/IC  

Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
CAUTI Challenge

CAUTI CHALLENGE TODAY (TM) is a part of your Urology Insights newsletter subscription. Access the latest commentary from CAUTI Expert Diane K. Newman, recent publications and experiences from those in the CAUTI treatment community.
Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board
UIJ

UroToday International Journal is a peer-reviewed, online publication featuring many types of articles about clinical urology and basic research in urology.
No Cost
There is no charge to submit, or publish an article in the UroToday International Journal. Additionally, there are no charges for color figures.
.....
Experience the new UroToday

UroToday has been free, providing open access to Urology content online since 2003. The challenging economic environment driving higher costs has resulted in our needing to charge for subscription access.  All sponsored content will remain free and open to readers.  We are committed to continue providing the highest quality, evidence-based urological information, keeping our subscribers up to date.


Uro Today
  • Improved access to key content
  • Dynamic user experience
  • Extensive archives dating back to 2003
Uro Today International Journal
  • Expeditious publishing
  • Engaging new media
  • Credible, international Editorial Board

Exclusive Headlines

GU Cancers Symposium 2012 - Role of dose escalation and supplemental androgen deprivation - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. Daniel Krauss addressed the role of dose escalation and supplemental androgen deprivation therapy (ADT).

see full text
GU Cancers Symposium 2012 - Hypofractionation for prostate cancer: Is less better? - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. W. Robert Lee expressed the potential advantages of a hypofractionation schedule (using fewer fractions with larger doses per fraction)

see full text
GU Cancers Symposium 2012 - Approved agents and related trials - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. Gary MacVicar challenged the GU Symposium audience to effectively sequence, combine therapies, and target treatments to men with metastatic CRPC.

see full text
GU Cancers Symposium 2012 - Sequencing of therapies in men with castration-resistant prostate cancer - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. Phillip Kantoff provided perspective on the optimal sequencing of existing agents for the treatment of mCRPC.

see full text

BJU Int Mini Reviews

UroToday News

Penile metastasis of prostatic adenocarcinoma. Case report - Abstract

OBJECTIVE: Penile metastases are late manifestations of a primary tumor, and they are a sign of poor prognosis.

see full text
Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer - Abstract

PURPOSE: There is currently no imaging biomarker for metastatic prostate cancer.

see full text
An opposed matched field IMRT technique for prostate cancer patients with bilateral prosthetic hips - Abstract

Intensity-modulated radiation therapy (IMRT) has gained wide-spread use for treating patients with prostate cancer, yet developing a plan for patients with bi-lateral metal hip prostheses implants may be challenging.

see full text
A study of segment weight optimization with the CMS XiO step-and-shoot IMRT technique for prostate cancer - Abstract

The aim of this study was to compare IMRT optimization in the CMS XiO radiotherapy treatment planning system, with and without segment weight optimization.

see full text

Share |